Partial
Mostly Unaligned
Patient Risk:
Moderate
Summary
Several factual safety/efficacy statements about lorazepam (e.g., insomnia/anxiety, sedation/dizziness, paradoxical reactions, dependence/withdrawal including seizures) are supported by the provided labeling text. However, multiple claims are unsupported or exceed the label excerpts provided (notably distribution/manufacturer and the specific GABA mechanism).
Category Scores
Accurate Statements
Lorazepam is a benzodiazepine.
DRUG ABUSE AND DEPENDENCE: "Ativan is a benzodiazepine and a CNS depressant..."
Ativan (lorazepam) is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms.
INDICATIONS AND USAGE: "indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms."
The effectiveness of Ativan in long-term use (more than 4 months) has not been assessed by systematic clinical studies; the physician should periodically reassess usefulness.
INDICATIONS AND USAGE: "The effectiveness of Ativan...in long-term use, that is, more than 4 months, has not been assessed...The physician should periodically reassess..."
Common adverse reactions include sedation and dizziness; the provided label lists sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%).
ADVERSE REACTIONS: "most frequent...sedation (15.9%), followed by dizziness (6.9%), weakness (4.2%), and unsteadiness (3.4%)."
Paradoxical reactions including anxiety/agitation/hostility/aggression/rage/sleep disturbances/insomnia and hallucinations may occur.
ADVERSE REACTIONS: "Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur."
Dependence and withdrawal can occur; Ativan may produce physical dependence and abrupt discontinuation/rapid reduction may precipitate acute withdrawal reactions including seizures.
DRUG ABUSE AND DEPENDENCE: "Ativan may produce physical dependence...manifested by withdrawal signs and symptoms...Abrupt discontinuation or rapid dosage reduction...may precipitate acute withdrawal reactions, including seizures..."
Acute withdrawal signs and symptoms can include insomnia and memory impairment.
DRUG ABUSE AND DEPENDENCE: Acute withdrawal list includes "insomnia" and "memory impairment".
Lorazepam can cause paradoxical increase in agitation/aggression (paradoxical reactions).
ADVERSE REACTIONS: "Paradoxical reactions...agitation...hostility, aggression, rage... may occur."
Lorazepam has potential for abuse and addiction (schedule IV; benzodiazepine with potential for abuse and addiction).
DRUG ABUSE AND DEPENDENCE: "Ativan contains lorazepam, a Schedule IV controlled substance." and "Ativan is a benzodiazepine...with a potential for abuse and addiction..."
Concomitant use of benzodiazepines and opioids increases the risk of respiratory depression; dosage/duration should be limited and patients monitored closely for respiratory depression and sedation.
DRUG INTERACTIONS: "concomitant use...increases the risk of respiratory depression...Limit dosage and duration...and monitor patients closely..."
Unsupported Statements
Ativan is manufactured by various pharmaceutical companies globally.
No manufacturing/distributor information is provided in the supplied label excerpts.
The specific manufacturing location of Ativan can depend on the region and the distributor.
No manufacturing location or regional variation information is provided in the supplied label excerpts.
In the United States, Ativan is distributed by UCB Pharma.
No U.S. distributor attribution is provided in the supplied label excerpts.
Globally, other companies may produce lorazepam under different brand names or as generics.
The supplied labeling excerpts do not address other companies/brands/generics or market availability.
Numerous pharmaceutical manufacturers produce lorazepam.
The supplied labeling excerpts do not address the number of manufacturers.
Generic versions of lorazepam become available after patent expirations.
The supplied labeling excerpts do not address patents or generic entry.
The original patents for lorazepam have long expired.
The supplied labeling excerpts do not address patent status.
The expiry of secondary patents on specific formulations or delivery methods might also be relevant for market entry of new products.
The supplied labeling excerpts do not address secondary patents or market entry.
Lorazepam works by enhancing the effect of gamma-aminobutyric acid (GABA) in the brain.
No mechanism statement about GABA enhancing effects is present in the provided CLINICAL PHARMACOLOGY or other excerpts. (The label excerpt only notes benzodiazepines interact at GABA-A sites in the context of opioid interaction.)
GABA is an inhibitory neurotransmitter that reduces nerve activity.
The provided labeling excerpts do not define GABA as inhibitory or describe its function.
By increasing the effects of GABA, lorazepam calms the central nervous system.
Not explicitly stated in the provided label excerpts as a mechanistic chain connecting increased GABA effects to calming.
Lorazepam’s therapeutic effects include treating insomnia.
The provided INDICATIONS AND USAGE excerpt supports short-term relief of anxiety symptoms and anxiety associated with depressive symptoms, and does not state insomnia as an indication. While the label lists insomnia as a paradoxical reaction and as a withdrawal symptom, it is not labeled as a therapeutic indication.
Ativan (lorazepam) is used to manage agitation.
Agitation appears in paradoxical reactions/withdrawal lists, but the provided INDICATIONS AND USAGE excerpts do not list agitation as an indication.
Ativan (lorazepam) is used as a pre-anesthetic medication to reduce anxiety before medical procedures.
Pre-anesthetic use is not present in the provided INDICATIONS AND USAGE excerpt.
Lorazepam is used in some cases to manage symptoms of status epilepticus, a prolonged seizure.
Status epilepticus is mentioned only in overdose/flumazenil contraindication context, not as an indication for lorazepam in the provided excerpts.
The potential for dependence and addiction is especially higher with long-term use or when taken at higher doses than prescribed.
The label excerpt supports higher risk of withdrawal adverse reactions with higher dosages and longer durations of use, but does not explicitly state that abuse/addiction potential is especially higher with long-term use or higher-than-prescribed doses in the provided sections.
Withdrawal symptoms from lorazepam can include rebound anxiety.
Rebound anxiety is not explicitly listed in the provided withdrawal signs/symptoms.
Lorazepam is a controlled substance in many countries due to its potential for abuse and dependence.
The provided label excerpt specifies Schedule IV (U.S.) but does not state it is controlled in many countries.
Lorazepam’s manufacturing, distribution, and prescription are subject to strict regulations by health authorities such as the FDA in the United States.
No such regulatory narrative appears in the provided labeling excerpts.
Regulations for lorazepam aim to ensure the drug’s safety and efficacy while preventing misuse.
No such regulatory objective statement appears in the provided labeling excerpts.
Contradictions
Low
AI Statement
Lorazepam’s therapeutic effects include treating insomnia.
Label Reference
INDICATIONS AND USAGE provides anxiety-management/short-term relief of anxiety symptoms and anxiety associated with depressive symptoms; insomnia is not stated as a labeled indication in the provided excerpt.
Important Omissions
No discussion of contraindications (e.g., hypersensitivity to benzodiazepines/components; acute narrow-angle glaucoma).
Importance:
Moderate
No mention of opioid coadministration warning specifics (e.g., dosage/duration limitation and monitoring for respiratory depression/sedation).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims overreach beyond the supplied label excerpts (e.g., insomnia as a therapeutic indication; non-support for mechanism/GABA explanations; agitation/status epilepticus/pre-anesthetic use not supported as indications in the excerpts). The dependence/withdrawal and paradoxical reaction content largely aligns, but unsupported/overextended indication claims could mislead about labeled uses.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Unaligned
Primary Issue
Multiple statements are unsupported by the provided FDA-label excerpts, including specific distribution/manufacturer/patent/generic-market claims and several treatment indications not present in the label excerpt (insomnia as indication; agitation; pre-anesthetic use; status epilepticus).
Suggested Improvement
Restrict claims to the provided label text: keep indications to anxiety disorders/short-term relief of anxiety symptoms as stated; use only label-supported adverse reactions (sedation/dizziness, paradoxical reactions, confusion/memory impairment) and dependence/withdrawal details; remove or qualify unsupported non-label facts (GABA mechanism phrasing, distributor/manufacturer, patent/generic entry, and additional off-label indications).